Lead Product(s) : SIL-204
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Silexion Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development
Details : Through the collaboration, Evonik’s proprietary biodegradable long-acting PLGA microparticle formulation will used for SIL-204, Silexion’s siRNA candidate for KRAS mutated Pancreatic cancer.
Product Name : SIL-204
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
December 17, 2024
Lead Product(s) : SIL-204
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Silexion Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Cellulose
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : JeNaCell
Deal Size : Not Applicable
Deal Type : Not Applicable
Evonik Company JenaCell Launches Wound Dressing Epicite® Balance for Chronic Wounds
Details : epicite® balance is made of biosynthetic cellulose, a hydropolymer for innovative medical device applications. The dressing enables superior wound cleansing effects and reactivates the healing of slow-healing wounds.
Product Name : Epicite® Balance
Product Type : Large molecule
Upfront Cash : Not Applicable
July 14, 2023
Lead Product(s) : Cellulose
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : JeNaCell
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cellulose
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : JeNaCell
Deal Size : Not Applicable
Deal Type : Not Applicable
Evonik Company JeNaCell Launches Wound Dressing Epicite® Balance for Chronic Wounds
Details : epicite® balance is made of biosynthetic cellulose, a hydropolymer for innovative medical device applications. The dressing enables superior wound cleansing effects and reactivates the healing of slow-healing wounds.
Product Name : Epicite® Balance
Product Type : Large molecule
Upfront Cash : Not Applicable
June 13, 2023
Lead Product(s) : Cellulose
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : JeNaCell
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bupivacaine
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Allay Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ATX-101 is a small product placed directly into the TKA surgical site in a simple, ‘place & go’ manner designed to add minimal extra complexity and time to the procedure.
Product Name : ATX-101
Product Type : Small molecule
Upfront Cash : Not Applicable
December 13, 2022
Lead Product(s) : Bupivacaine
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Allay Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Phathom Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Evonik and Phathom Pharmaceuticals Partner to Produce Novel Acid-Blocker Vonoprazan
Details : Vonoprazan is a novel potassium-competitive acid blocker (PCAB). It inhibits gastric acid secretion by acting as a reversible competitive inhibitor against potassium ions.
Product Name : Voquezna Triple Pack
Product Type : Small molecule
Upfront Cash : Undisclosed
October 24, 2022
Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Phathom Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : mRNA-based Therapy
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : BARDA
Deal Size : $220.0 million
Deal Type : Funding
Details : Lipids, molecules that make up the building blocks of living cells, are critical to producing mRNA-based drugs. The mRNA is enclosed in a lipid nanoparticle (LNP) composed of specific lipids. The LNP protects the mRNA and delivers it safely into the cell...
Product Name : Undisclosed
Product Type : Large molecule
Upfront Cash : Undisclosed
June 02, 2022
Lead Product(s) : mRNA-based Therapy
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : BARDA
Deal Size : $220.0 million
Deal Type : Funding
Lead Product(s) : Simufilam
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Cassava Sciences
Deal Size : Undisclosed
Deal Type : Agreement
Evonik and Cassava Sciences Join Forces to Fight Alzheimer’s Disease
Details : Evonik to supply commercial quantities of simufilam, a drug candidate for the treatment of Alzheimer’s disease. Simufilam is a novel drug, discovered at Cassava Sciences, that targets both neuroinflammation and neurodegeneration.
Product Name : PTI-125
Product Type : Small molecule
Upfront Cash : Undisclosed
March 09, 2021
Lead Product(s) : Simufilam
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Cassava Sciences
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Tozinameran
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : BioNTech
Deal Size : Undisclosed
Deal Type : Partnership
Evonik Strengthens Strategic Partnership with Biontech on Covid-19 Vaccine
Details : Lipids are fundamental to produce highly effective mRNA-based vaccines. Only with an increase in lipid supply can the volume of vaccine be further increased. This move marks an expansion of the partnership between Evonik and the Comirnaty, vaccine manufa...
Product Name : Comirnaty
Product Type : Vaccine
Upfront Cash : Undisclosed
February 11, 2021
Lead Product(s) : Tozinameran
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : BioNTech
Deal Size : Undisclosed
Deal Type : Partnership
KEY SERVICES
Reset All
Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!
